Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 19 studies | 50% ± 11% | |
lung | 18 studies | 51% ± 17% | |
intestine | 11 studies | 52% ± 20% | |
kidney | 9 studies | 54% ± 14% | |
eye | 8 studies | 38% ± 19% | |
lymph node | 7 studies | 51% ± 20% | |
brain | 7 studies | 28% ± 9% | |
bone marrow | 6 studies | 35% ± 16% | |
liver | 6 studies | 43% ± 16% | |
pancreas | 5 studies | 60% ± 21% | |
uterus | 5 studies | 48% ± 16% | |
placenta | 4 studies | 50% ± 19% | |
prostate | 4 studies | 47% ± 19% | |
breast | 4 studies | 58% ± 5% | |
adrenal gland | 3 studies | 49% ± 10% | |
esophagus | 3 studies | 53% ± 12% | |
skin | 3 studies | 47% ± 20% | |
thymus | 3 studies | 72% ± 29% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 100% | 19110.73 | 328 / 328 | 100% | 455.23 | 178 / 178 |
stomach | 100% | 20145.69 | 359 / 359 | 100% | 948.95 | 286 / 286 |
esophagus | 100% | 14073.09 | 1444 / 1445 | 100% | 618.76 | 183 / 183 |
intestine | 100% | 19786.90 | 966 / 966 | 100% | 1171.26 | 525 / 527 |
uterus | 100% | 6689.79 | 170 / 170 | 100% | 815.38 | 457 / 459 |
lung | 100% | 12838.98 | 576 / 578 | 100% | 708.40 | 1152 / 1155 |
ovary | 100% | 5759.16 | 180 / 180 | 99% | 516.20 | 427 / 430 |
skin | 100% | 14769.40 | 1809 / 1809 | 99% | 746.20 | 468 / 472 |
brain | 99% | 7324.94 | 2610 / 2642 | 100% | 427.05 | 704 / 705 |
bladder | 100% | 9977.00 | 21 / 21 | 99% | 851.15 | 497 / 504 |
breast | 100% | 8708.06 | 459 / 459 | 99% | 524.62 | 1102 / 1118 |
liver | 100% | 9285.38 | 225 / 226 | 98% | 487.79 | 398 / 406 |
prostate | 100% | 6595.16 | 245 / 245 | 97% | 380.51 | 488 / 502 |
thymus | 100% | 7509.37 | 651 / 653 | 96% | 360.61 | 582 / 605 |
kidney | 100% | 21531.92 | 89 / 89 | 96% | 486.39 | 863 / 901 |
adrenal gland | 100% | 9594.40 | 258 / 258 | 90% | 304.69 | 206 / 230 |
eye | 0% | 0 | 0 / 0 | 100% | 613.95 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 999.42 | 29 / 29 |
spleen | 100% | 10173.18 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 1026.39 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 200.17 | 1 / 1 |
adipose | 100% | 9193.10 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 7427.74 | 1331 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 95% | 10112.05 | 880 / 929 | 0% | 0 | 0 / 0 |
heart | 94% | 6072.41 | 807 / 861 | 0% | 0 | 0 / 0 |
muscle | 36% | 1221.71 | 293 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0051503 | Biological process | adenine nucleotide transport |
GO_0007059 | Biological process | chromosome segregation |
GO_1990830 | Biological process | cellular response to leukemia inhibitory factor |
GO_1901029 | Biological process | negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway |
GO_1990845 | Biological process | adaptive thermogenesis |
GO_0030218 | Biological process | erythrocyte differentiation |
GO_0015853 | Biological process | adenine transport |
GO_1901526 | Biological process | positive regulation of mitophagy |
GO_1990544 | Biological process | mitochondrial ATP transmembrane transport |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0046902 | Biological process | regulation of mitochondrial membrane permeability |
GO_0030183 | Biological process | B cell differentiation |
GO_1902600 | Biological process | proton transmembrane transport |
GO_0140021 | Biological process | mitochondrial ADP transmembrane transport |
GO_0005886 | Cellular component | plasma membrane |
GO_0042645 | Cellular component | mitochondrial nucleoid |
GO_0016020 | Cellular component | membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0005743 | Cellular component | mitochondrial inner membrane |
GO_0071817 | Cellular component | MMXD complex |
GO_0005757 | Cellular component | mitochondrial permeability transition pore complex |
GO_0005634 | Cellular component | nucleus |
GO_0015078 | Molecular function | proton transmembrane transporter activity |
GO_0000295 | Molecular function | adenine nucleotide transmembrane transporter activity |
GO_0015207 | Molecular function | adenine transmembrane transporter activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0005471 | Molecular function | ATP:ADP antiporter activity |
GO_0003723 | Molecular function | RNA binding |
GO_0017077 | Molecular function | oxidative phosphorylation uncoupler activity |
GO_0005515 | Molecular function | protein binding |
Gene name | SLC25A5 |
Protein name | ADP/ATP translocase 2 (ADP,ATP carrier protein 2) (ADP,ATP carrier protein, fibroblast isoform) (Adenine nucleotide translocator 2) (ANT 2) (Solute carrier family 25 member 5) [Cleaved into: ADP/ATP translocase 2, N-terminally processed] ADP/ATP translocase (ADP,ATP carrier protein) |
Synonyms | ANT2 AAC2 |
Description | FUNCTION: ADP:ATP antiporter that mediates import of ADP into the mitochondrial matrix for ATP synthesis, and export of ATP out to fuel the cell (By similarity). Cycles between the cytoplasmic-open state (c-state) and the matrix-open state (m-state): operates by the alternating access mechanism with a single substrate-binding site intermittently exposed to either the cytosolic (c-state) or matrix (m-state) side of the inner mitochondrial membrane (By similarity). In addition to its ADP:ATP antiporter activity, also involved in mitochondrial uncoupling and mitochondrial permeability transition pore (mPTP) activity (By similarity). Plays a role in mitochondrial uncoupling by acting as a proton transporter: proton transport uncouples the proton flows via the electron transport chain and ATP synthase to reduce the efficiency of ATP production and cause mitochondrial thermogenesis (By similarity). Proton transporter activity is inhibited by ADP:ATP antiporter activity, suggesting that SLC25A5/ANT2 acts as a master regulator of mitochondrial energy output by maintaining a delicate balance between ATP production (ADP:ATP antiporter activity) and thermogenesis (proton transporter activity) (By similarity). Proton transporter activity requires free fatty acids as cofactor, but does not transport it (By similarity). Probably mediates mitochondrial uncoupling in tissues that do not express UCP1 (By similarity). Also plays a key role in mPTP opening, a non-specific pore that enables free passage of the mitochondrial membranes to solutes of up to 1.5 kDa, and which contributes to cell death . It is however unclear if SLC25A5/ANT2 constitutes a pore-forming component of mPTP or regulates it (By similarity). Acts as a regulator of mitophagy independently of ADP:ATP antiporter activity: promotes mitophagy via interaction with TIMM44, leading to inhibit the presequence translocase TIMM23, thereby promoting stabilization of PINK1 (By similarity). As part of the mitotic spindle-associated MMXD complex it may play a role in chromosome segregation . . FUNCTION: Catalyzes the exchange of ADP and ATP across the membrane. . |
Accessions | ENST00000317881.9 Q6NVC0 P05141 |